Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Ropeginterferon ALFA-2B

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Clinical Review of Pegylated Interferons Suggests Formulation
    Clinical Review of Pegylated Interferons Suggests Formulation

    21 Feb 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240221809028/en

    BUSINESSWIRE
    21 Feb 2024
    Share Share
    Presentations at MPN Congress Reinforce Role of ropeginterferon alfa-2b-njft
    Presentations at MPN Congress Reinforce Role of ropeginterferon alfa-2b-njft

    02 Nov 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231102403190/en

    BUSINESSWIRE
    02 Nov 2023
    Share Share
    Ropeginterferon Alfa-2b Produces Responses,Safety in Prefibrotic P Myelofibrosis
    Ropeginterferon Alfa-2b Produces Responses,Safety in Prefibrotic P Myelofibrosis

    30 Jun 2023

    // ONCLIVE

    https://www.onclive.com/view/ropeginterferon-alfa-2b-produces-responses-safety-in-prefibrotic-primary-myelofibrosis

    ONCLIVE
    30 Jun 2023
    Share Share
    PharmaEssentia Selects Pint-Pharma as Commercial Partner for BESREMi
    PharmaEssentia Selects Pint-Pharma as Commercial Partner for BESREMi

    02 Jun 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230602005191/en

    BUSINESSWIRE
    02 Jun 2023
    Share Share
    AOP Health: Completed Study Strengthens Development for ropeginterferon alpha 2b
    AOP Health: Completed Study Strengthens Development for ropeginterferon alpha 2b

    01 Jun 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230601005759/en

    BUSINESSWIRE
    01 Jun 2023
    Share Share
    NCCN Clinical Practice Guidelines in Oncology Updated to Recommend BESREMi
    NCCN Clinical Practice Guidelines in Oncology Updated to Recommend BESREMi

    23 May 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230523005317/en

    BUSINESSWIRE
    23 May 2023
    Share Share